New York, New York, September 15, 2026
Acurx Pharmaceuticals has announced the presentation of new preclinical microbiology data for ibezapolstat, its investigational antibiotic being developed for the treatment of Clostridioides difficile infection (CDI). The scientific poster will be presented at the International C. difficile Symposium (ICDS), a leading international scientific meeting focused on C. difficile research. The data demonstrate superior in vitro bacterial killing kinetics for ibezapolstat compared with vancomycin and fidaxomicin, two established standards of care, when tested in co-cultures containing C. difficile and vancomycin-resistant Enterococcus (VRE). The findings provide additional preclinical evidence supporting ibezapolstat’s potential as a targeted antibiotic approach for CDI and highlight its activity in a laboratory model designed to examine interactions between C. difficile and another clinically important bacterial pathogen.
Ibezapolstat Demonstrates Rapid In Vitro Killing
The scientific poster evaluates the in vitro kill kinetics of ibezapolstat in co-cultures containing C. difficile and VRE. This experimental model is designed to provide insight into how an antimicrobial agent performs when multiple bacterial species are present simultaneously, reflecting a more complex microbiological environment than a single-organism laboratory culture. According to Acurx, ibezapolstat demonstrated superior bacterial killing kinetics against C. difficile compared with both vancomycin and fidaxomicin in the co-culture model. The company is developing ibezapolstat as a targeted therapy intended to eliminate C. difficile while preserving beneficial bacteria within the intestinal microbiome. The distinction is important because treatment of CDI involves more than simply eliminating the disease-causing organism. Broad disruption of the gut microbiome can affect the ecological balance of intestinal bacteria and potentially contribute to conditions that allow C. difficile to recur. Consequently, researchers are investigating antibiotics that can provide effective pathogen control while minimizing unnecessary microbiome disruption.
Targeted Approach Addresses C. difficile Infection
Ibezapolstat is an investigational DNA polymerase IIIC inhibitor designed to selectively target C. difficile. The antibiotic’s mechanism is intended to interfere with bacterial DNA replication, ultimately preventing the pathogen from multiplying and supporting its elimination. Acurx’s development strategy is based on the concept of targeted antimicrobial therapy, with ibezapolstat designed to act against C. difficile while having a more limited impact on other components of the intestinal microbiome. This approach could be particularly valuable in CDI, where disruption of normal gut bacteria is associated with disease recurrence. Vancomycin and fidaxomicin remain important treatments for CDI, but recurrence continues to be a significant clinical challenge. New antibiotics with differentiated mechanisms and microbiome-sparing characteristics could therefore provide additional options for patients and healthcare professionals. The co-culture findings presented at ICDS are preclinical and should not be interpreted as evidence of clinical superiority in patients. In vitro results require confirmation through clinical studies before conclusions about patient outcomes can be established.
Advertisement
Research Supports Continued Antibiotic Development
The new findings add to the growing body of research surrounding ibezapolstat and its potential role in addressing C. difficile-associated disease. Scientific presentations at specialized meetings such as ICDS provide researchers with opportunities to examine antimicrobial activity, mechanisms of action and potential advantages over existing standards of care. The inclusion of VRE in the experimental model is also scientifically relevant because vancomycin-resistant Enterococcus is an important healthcare-associated organism and can coexist with C. difficile in the gastrointestinal tract. Studying antibiotic activity in a mixed bacterial environment can provide additional information about how a therapy may behave in more complex microbiological conditions.
Acurx continues to advance ibezapolstat through its drug-development program while evaluating its potential to address unmet needs in CDI. The company believes the investigational antibiotic’s targeted mechanism and microbiome-focused development strategy could differentiate it from existing treatment approaches. For cGxP.wire readers, the Acurx announcement represents a significant antibiotic research and biopharmaceutical development update. The reported in vitro findings add to the scientific understanding of ibezapolstat and its activity against C. difficile in a VRE-containing environment. As antimicrobial resistance and recurrent CDI remain important healthcare challenges, continued development of targeted antibiotics could contribute to the search for more effective and microbiome-conscious treatment strategies.Future clinical data will be important in determining whether the preclinical advantages observed with ibezapolstat translate into meaningful benefits for patients. Until then, the ICDS presentation provides another scientific milestone for Acurx’s investigational antibiotic program and highlights the continuing effort to develop new therapies for C. difficile infection.
Source: Acurx Pharmaceuticals press release
